Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 ``PembroRad'' randomized trial

J. Bourhis , C. Sire , Y. Tao , L. Martin , M. Alfonsi , J. B. Prevost , M. Rives , C. Lafond , J. M. Tourani , J. Biau , L. Geoffrois , Alexandre Coutte (1) , X. Liem , E. Vauleon , F. Drouet , A. Pechery , J. Guigay , M. Wanneveich , A. Auperin , X. Sun

1 CHIMERE - CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516

Domaines: Sciences du Vivant [q-bio]

J. Bourhis, C. Sire, Y. Tao, L. Martin, M. Alfonsi, et al.. Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 ``PembroRad'' randomized trial. Annals of Oncology, 2020, 31 (4), pp.S1168. ⟨10.1016/j.annonc.2020.08.2268⟩. ⟨hal-03600471⟩